Progenics Pharmaceuticals Announces Independent Committee’s Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404

NEW YORK, Dec. 22, 2016 -- (Healthcare Sales & Marketing Network) -- Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and other technologies for targeting and treating cancer, today announced that its independent ... Biopharmaceuticals, Oncology Progenics Pharmaceuticals, AZEDRA , imaging agent
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news